BCT vs. ONC, COV, SCYB, COM, NVH, IGX, TH, SVA, PDP, and EMH
Should you be buying BriaCell Therapeutics stock or one of its competitors? The main competitors of BriaCell Therapeutics include Oncolytics Biotech (ONC), Covalon Technologies (COV), Scythian Biosciences (SCYB), 138267 (COM.TO) (COM), Novoheart (NVH), IntelGenx Technologies (IGX), Theratechnologies (TH), Sernova (SVA), Pediapharm (PDP), and Emerald Health Therapeutics (EMH). These companies are all part of the "biotechnology" industry.
BriaCell Therapeutics vs.
BriaCell Therapeutics (TSE:BCT) and Oncolytics Biotech (TSE:ONC) are both small-cap medical companies, but which is the superior business? We will compare the two businesses based on the strength of their analyst recommendations, dividends, community ranking, valuation, risk, earnings, profitability, media sentiment and institutional ownership.
Oncolytics Biotech received 195 more outperform votes than BriaCell Therapeutics when rated by MarketBeat users. However, 100.00% of users gave BriaCell Therapeutics an outperform vote while only 74.81% of users gave Oncolytics Biotech an outperform vote.
BriaCell Therapeutics has a beta of 1.83, indicating that its stock price is 83% more volatile than the S&P 500. Comparatively, Oncolytics Biotech has a beta of 1.35, indicating that its stock price is 35% more volatile than the S&P 500.
15.0% of BriaCell Therapeutics shares are owned by institutional investors. Comparatively, 1.8% of Oncolytics Biotech shares are owned by institutional investors. 9.3% of BriaCell Therapeutics shares are owned by company insiders. Comparatively, 3.8% of Oncolytics Biotech shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.
Oncolytics Biotech's return on equity of -138.22% beat BriaCell Therapeutics' return on equity.
Oncolytics Biotech is trading at a lower price-to-earnings ratio than BriaCell Therapeutics, indicating that it is currently the more affordable of the two stocks.
Oncolytics Biotech has a consensus target price of C$3.50, indicating a potential upside of 136.49%. Given Oncolytics Biotech's stronger consensus rating and higher possible upside, analysts clearly believe Oncolytics Biotech is more favorable than BriaCell Therapeutics.
In the previous week, Oncolytics Biotech had 29 more articles in the media than BriaCell Therapeutics. MarketBeat recorded 29 mentions for Oncolytics Biotech and 0 mentions for BriaCell Therapeutics. Oncolytics Biotech's average media sentiment score of 0.11 beat BriaCell Therapeutics' score of 0.00 indicating that Oncolytics Biotech is being referred to more favorably in the news media.
Summary
Oncolytics Biotech beats BriaCell Therapeutics on 9 of the 15 factors compared between the two stocks.
Get BriaCell Therapeutics News Delivered to You Automatically
Sign up to receive the latest news and ratings for BCT and its competitors with MarketBeat's FREE daily newsletter.
New MarketBeat Followers Over Time
This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Media Sentiment Over Time
This chart shows the average media sentiment of TSE and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
BriaCell Therapeutics Competitors List
Related Companies and Tools
This page (TSE:BCT) was last updated on 11/19/2024 by MarketBeat.com Staff
Free BCT Stock Alerts